Perspective Therapeutics ... (CATX)
Perspective Therapeutics Statistics
Share Statistics
Perspective Therapeutics has 74.05M shares outstanding. The number of shares has increased by 9.82% in one year.
| Shares Outstanding | 74.05M |
| Shares Change (YoY) | 9.82% |
| Shares Change (QoQ) | 9.56% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 53.81M |
| Failed to Deliver (FTD) Shares | 5.56K |
| FTD / Avg. Volume | 0.78% |
Short Selling Information
The latest short interest is 5.02M, so 6.78% of the outstanding shares have been sold short.
| Short Interest | 5.02M |
| Short % of Shares Out | 6.78% |
| Short % of Float | 9.61% |
| Short Ratio (days to cover) | 4.32 |
Valuation Ratios
The PE ratio is -0.03 and the forward PE ratio is null. Perspective Therapeutics's PEG ratio is 0.
| PE Ratio | -0.03 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | 14 |
| PB Ratio | 0.01 |
| P/FCF Ratio | -0.03 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Perspective Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.68, with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.68 |
| Quick Ratio | 12.68 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.23 |
| Debt / FCF | -0.03 |
| Interest Coverage | -217.9 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-574.49K |
| Employee Count | 138 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.1M |
| Effective Tax Rate | 2.58% |
Stock Price Statistics
The stock price has increased by -85.71% in the last 52 weeks. The beta is 1.21, so Perspective Therapeutics's price volatility has been higher than the market average.
| Beta | 1.21 |
| 52-Week Price Change | -85.71% |
| 50-Day Moving Average | 2.35 |
| 200-Day Moving Average | 7.48 |
| Relative Strength Index (RSI) | 58.44 |
| Average Volume (20 Days) | 717.18K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | 10.46M |
| Net Income | -79.28M |
| EBITDA | 10.46M |
| EBIT | -81.42M |
| Earnings Per Share (EPS) | -123.06 |
Balance Sheet
The company has 61.58M in cash and 2.38M in debt, giving a net cash position of 59.2M.
| Cash & Cash Equivalents | 61.58M |
| Total Debt | 2.38M |
| Net Cash | 59.2M |
| Retained Earnings | -231.72M |
| Total Assets | 341.1M |
| Working Capital | 212.93M |
Cash Flow
In the last 12 months, operating cash flow was -18.29M and capital expenditures -54.41M, giving a free cash flow of -72.71M.
| Operating Cash Flow | -18.29M |
| Capital Expenditures | -54.41M |
| Free Cash Flow | -72.71M |
| FCF Per Share | -112.86 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CATX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CATX is $15, which is 517.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 517.3% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Stock Splits
The last stock split was on Jun 17, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 17, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 1.1 |
| Piotroski F-Score | 3 |